• Publications
  • Influence
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
PURPOSE We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derivedExpand
  • 442
  • 27
Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
PURPOSE New antiviral agents with activity against hepatitis C virus (HCV) are needed to optimize treatment for chronic hepatitis C (CHC). We evaluated the pharmacokinetics of setrobuvir (aExpand
  • 7
  • 1
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
BACKGROUND ANA773, an oral prodrug of a small-molecule Toll-like receptor (TLR)7 agonist, induces a dose-related decrease in serum HCV RNA levels in chronic hepatitis C patients. METHODS TheExpand
  • 24
Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.
2524 Background: ANA773 is an oral prodrug of a small molecule, TLR7-selective agonist which has demonstrated pharmacological activity in preclinical studies. In a study in healthy volunteers,Expand
  • 1